Phase 2 Liver Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with hepatocellular carcinoma (a type of liver cancer) based on tissue testing or imaging scans
• People who have at least one liver tumour that can be treated with a procedure called TACE (a targeted treatment delivered directly to the tumour through blood vessels)
• People whose liver function falls within a specific range known as Child-Pugh A or B7 (a scoring system used to assess liver health)
• People who are not suitable for surgery to remove the tumour or for a liver transplant
• People aged 18 or older
• People who are well enough to carry out basic daily activities (based on a standard medical scale called ECOG, with a score of 2 or below)
• People who have at least one tumour that can be measured on scans — either untreated or one that has grown back after a previous local treatment
• People whose blood test results show their organs (including liver, kidneys, and bone marrow) are functioning well enough, based on specific laboratory values (confirm with trial site)
• People who are able to use effective contraception during the trial and for several months after treatment ends, as the study drugs may harm an unborn baby (the required duration varies by drug — confirm with trial site)
• People with a life expectancy of more than 3 months
• People who are able to swallow tablets
• People who are willing and able to read and sign a consent form agreeing to participate

Who may not be able to join:

• People who have previously received any type of systemic (whole-body) anti-cancer treatment
• People who still have significant side effects from a previous cancer treatment (other than hair loss), which have not returned to a mild or baseline level
• People who have had any local liver treatment within the past 3 months
• People who have a specific type of blood clot in the main vein supplying the liver (called Vp3 or Vp4 portal vein thrombus)
• People whose cancer has spread outside the liver
• People who are currently taking part in another clinical trial with an investigational treatment
• People who have had a serious allergic reaction to nivolumab, cabozantinib, or similar medications used in this study
• People taking certain blood-thinning medications, including warfarin, dabigatran, rivaroxaban, or clopidogrel (some low-dose or low molecular weight heparin options may be allowed — confirm with trial site)
• People whose blood clotting test results are above a certain level within 28 days before the first dose (confirm with trial site)
• People with serious uncontrolled health conditions, including active infection, heart failure, blood pressure that remains too high despite treatment, a stroke or heart attack within the past 6 months, unstable chest pain, irregular heart rhythm, or certain digestive tract problems such as bowel perforation, active ulcers, or inflammation of the bowel
• People who have had significant bleeding (such as coughing or vomiting blood) within the past 12 weeks
• People with certain lung lesions or tumours growing into major blood vessels outside the liver
• People with serious unhealed wounds, uncontrolled thyroid problems, or moderate to severe liver disease (Child-Pugh B or C)
• People with mental health or personal circumstances that would make it difficult to follow the trial requirements
• People who have had major surgery within 2 weeks, or minor surgery within 10 days, before the first dose, or who have not fully healed from a previous surgery
• People who have previously been treated with cabozantinib
• People whose heart electrical activity (measured by an ECG) shows a specific abnormality called a prolonged QTcF interval above 500 ms within 28 days before the first dose
• People who have taken a type of cancer medication called a small molecule kinase inhibitor within 2 weeks before the first dose
• People who have had another primary cancer within the past 3 years, with some exceptions such as certain skin cancers, early-stage prostate cancer, or cervical cancer in an early stage that was treated without systemic therapy
• People who are pregnant or breastfeeding
• People who have a specific rare subtype of liver cancer called fibrolamellar HCC
• People who have received any systemic anti-cancer therapy, including experimental treatments, within 4 weeks before joining the trial
• People who have had radiation therapy within 2 to 4 weeks before the first dose (the timeframe depends on the type of radiation — confirm with trial site), or treatment with radioactive substances within 6 weeks
• People who have received a live vaccine within 30 days before the first dose (certain inactivated flu vaccines may be allowed — confirm with trial site)
• People who have an immune system condition, or who are taking high-dose steroid or immunosuppressant medications within 7 days before the first dose (replacement hormone therapies for certain conditions may be allowed — confirm with trial site)
• People who have had a severe allergic reaction (Grade 3 or higher) to nivolumab or cabozantinib
• People who have an active autoimmune disease that has required systemic medical treatment in the past 2 years (hormone replacement therapies for certain conditions are generally not considered systemic treatment — confirm with trial site)
• People who have a history of lung inflammation (pneumonitis) that required steroid treatment, or who currently have pneumonitis
• People who have an active infection requiring systemic treatment
• People with a known history of HIV infection
• People with a known history of active tuberculosis (TB)
• People with any other condition, treatment history, or lab result that the treating doctor believes would make trial participation unsafe or unsuitable

Important: Always verify eligibility with the trial site directly before applying.